Loading clinical trials...
Loading clinical trials...
A Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer.
Conditions
Interventions
PRGN-2009 plus Pembrolizumab
Locations
3
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
National Institute of Health
Bethesda, Maryland, United States
University of Washington
Seattle, Washington, United States
Start Date
November 11, 2025
Primary Completion Date
November 11, 2026
Completion Date
November 30, 2030
Last Updated
April 23, 2026
NCT04895709
NCT04977453
NCT06349642
NCT05639972
NCT07225530
NCT07209917
Lead Sponsor
Precigen, Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions